Viridian Therapeutics, Inc.\DE (VRDN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $19.56, +6.42% vs the prior close of $18.38.
- Volume 2.17M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VRDN jumps 6.4% to $19.56. Closed at $19.56, +6.42% vs the prior close of $18.38. Day range $18.53–$19.78, opened at $18.69.
VRDN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — VRDN jumps 6.4% to $19.56
- Closed at $19.56, +6.42% vs the prior close of $18.38. Day range $18.53–$19.78, opened at $18.69.
- Volume was 2.17M shares, 1.2x its 50-day average of 1.78M.
- Price is -10.0% vs its 50-day average ($21.73) and -12.0% vs its 200-day average ($22.22).
- 52-week range $13.18–$34.29; today's close sits at 30% of that range, 43.0% below the 52-week high.
Oct 14, 2026 — VRDN rises 0.9% to $18.38 on 2.1x normal volume
- Closed at $18.38, +0.88% vs the prior close of $18.22. Day range $18.01–$18.75, opened at $18.19.
- Volume was 3.73M shares, 2.1x its 50-day average of 1.74M — unusually heavy trading.
- Price is -15.5% vs its 50-day average ($21.76) and -17.5% vs its 200-day average ($22.28).
- 52-week range $13.18–$34.29; today's close sits at 25% of that range, 46.4% below the 52-week high.
Oct 13, 2026 — VRDN dips 0.4% to $18.22
- Closed at $18.22, -0.44% vs the prior close of $18.30. Day range $17.96–$18.33, opened at $18.04.
- Volume was 2.12M shares, 1.2x its 50-day average of 1.74M.
- Price is -16.5% vs its 50-day average ($21.81) and -18.5% vs its 200-day average ($22.35).
- 52-week range $13.18–$34.29; today's close sits at 24% of that range, 46.9% below the 52-week high.
Oct 12, 2026 — VRDN dips 1.9% to $18.30
- Closed at $18.30, -1.93% vs the prior close of $18.66. Day range $18.21–$19.18, opened at $19.00.
- Volume was 1.95M shares, 1.1x its 50-day average of 1.72M.
- Price is -16.2% vs its 50-day average ($21.83) and -18.4% vs its 200-day average ($22.42).
- 52-week range $13.18–$34.29; today's close sits at 24% of that range, 46.6% below the 52-week high.
Oct 9, 2026 — VRDN rises 1.7% to $18.66, 3 up days in a row
- Closed at $18.66, +1.74% vs the prior close of $18.34. Day range $18.16–$18.72, opened at $18.31.
- Volume was 1.33M shares, 0.8x its 50-day average of 1.72M.
- Price is -14.6% vs its 50-day average ($21.84) and -17.0% vs its 200-day average ($22.49).
- 52-week range $13.18–$34.29; today's close sits at 26% of that range, 45.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — VRDN rises 0.3% to $18.34
- Closed at $18.34, +0.33% vs the prior close of $18.28. Day range $17.59–$18.44, opened at $18.02.
- Volume was 2.44M shares, 1.4x its 50-day average of 1.71M.
- Price is -16.1% vs its 50-day average ($21.87) and -18.7% vs its 200-day average ($22.56).
- 52-week range $13.18–$34.29; today's close sits at 24% of that range, 46.5% below the 52-week high.
Oct 7, 2026 — VRDN rises 0.3% to $18.28
- Closed at $18.28, +0.33% vs the prior close of $18.22. Day range $17.92–$18.73, opened at $18.02.
- Volume was 1.69M shares, 1.0x its 50-day average of 1.70M.
- Price is -16.5% vs its 50-day average ($21.90) and -19.2% vs its 200-day average ($22.62).
- 52-week range $13.18–$34.29; today's close sits at 24% of that range, 46.7% below the 52-week high.
Oct 6, 2026 — VRDN slides 4.1% to $18.22, a 1-month low
- Closed at $18.22, -4.11% vs the prior close of $19.00. Day range $18.07–$19.13, opened at $19.00.
- Volume was 2.20M shares, 1.3x its 50-day average of 1.70M.
- Price is -16.9% vs its 50-day average ($21.92) and -19.7% vs its 200-day average ($22.69).
- 52-week range $13.18–$34.29; today's close sits at 24% of that range, 46.9% below the 52-week high.
Oct 5, 2026 — VRDN dips 2.1% to $19.00
- Closed at $19.00, -2.06% vs the prior close of $19.40. Day range $18.83–$19.59, opened at $19.41.
- Volume was 2.65M shares, 1.6x its 50-day average of 1.68M.
- Price is -13.5% vs its 50-day average ($21.95) and -16.5% vs its 200-day average ($22.76).
- 52-week range $13.18–$34.29; today's close sits at 28% of that range, 44.6% below the 52-week high.
Oct 2, 2026 — VRDN rises 2.2% to $19.40
- Closed at $19.40, +2.16% vs the prior close of $18.99. Day range $18.92–$19.55, opened at $19.16.
- Volume was 1.52M shares, 0.9x its 50-day average of 1.67M.
- Price is -11.7% vs its 50-day average ($21.96) and -15.0% vs its 200-day average ($22.83).
- 52-week range $13.18–$34.29; today's close sits at 29% of that range, 43.4% below the 52-week high.
VRDN latest news & SEC filings
Every SEC filing by or about VRDN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tousignant Jennifer sold 10,000 shares at $24.50 (≈$245.00K) on Aug 19, 2026
- Tousignant Jennifer sold 4,212 shares at $24.50 (≈$103.19K) on Aug 19, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$127.12M (prior year -$100.73M) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade VRDN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 26, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.34% (largest 7.8%).
- Liquidity: about 2.24M shares (≈$43.91M) trade per day on average.
- 52-week position: $19.56 vs a range of $13.18–$34.29 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 6 open-market buys, 3 sales; latest: Jennifer Tousignant sold 10,000 shares on Aug 19, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 29, 2026.
- Share count: 113.29M shares outstanding (Aug 3, 2026), +38.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VRDN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 18.69 | 19.78 | 18.53 | 19.56 | 2.17M |
| Oct 14, 2026 | 18.19 | 18.75 | 18.01 | 18.38 | 3.73M |
| Oct 13, 2026 | 18.04 | 18.33 | 17.96 | 18.22 | 2.12M |
| Oct 12, 2026 | 19.00 | 19.18 | 18.21 | 18.30 | 1.95M |
| Oct 9, 2026 | 18.31 | 18.72 | 18.16 | 18.66 | 1.33M |
| Oct 8, 2026 | 18.02 | 18.44 | 17.59 | 18.34 | 2.44M |
| Oct 7, 2026 | 18.02 | 18.73 | 17.92 | 18.28 | 1.69M |
| Oct 6, 2026 | 19.00 | 19.13 | 18.07 | 18.22 | 2.20M |
| Oct 5, 2026 | 19.41 | 19.59 | 18.83 | 19.00 | 2.65M |
| Oct 2, 2026 | 19.16 | 19.55 | 18.92 | 19.40 | 1.52M |
| Oct 1, 2026 | 20.61 | 20.61 | 18.99 | 18.99 | 3.38M |
| Sep 30, 2026 | 20.27 | 20.75 | 20.00 | 20.59 | 1.40M |
| Sep 29, 2026 | 20.68 | 20.85 | 19.73 | 20.00 | 1.23M |
| Sep 28, 2026 | 20.31 | 20.70 | 20.03 | 20.57 | 1.34M |
| Sep 25, 2026 | 20.75 | 21.00 | 20.16 | 20.47 | 2.09M |
| Sep 24, 2026 | 21.10 | 21.25 | 20.22 | 20.66 | 2.21M |
| Sep 23, 2026 | 22.11 | 22.18 | 21.20 | 21.43 | 2.86M |
| Sep 22, 2026 | 22.02 | 22.33 | 21.54 | 22.12 | 1.46M |
| Sep 21, 2026 | 22.28 | 22.40 | 21.53 | 21.58 | 1.75M |
| Sep 18, 2026 | 21.99 | 22.17 | 21.80 | 22.00 | 5.38M |
About Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE (VRDN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1590750.
VRDN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey Robert Ajer | Director | Jul 2, 2026 |
| Christopher W. Cain | Director | Jul 2, 2026 |
| Funds Management Llc Fairmount | Director | May 13, 2026 |
| Healthcare Fund Ii Gp Llc Fairmount | Director | May 13, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | May 13, 2026 |
| Sarah Gheuens | Director | Jul 2, 2026 |
| Tomas Kiselak | Director | Jul 2, 2026 |
| Stephen F. Mahoney | President and CEO | Mar 9, 2026 |
| Arlene Morris | Director | Jul 2, 2026 |
| Jennifer K. Moses | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas W. Beetham | Chief Operating Officer | Mar 9, 2026 |
| Seth Harmon | Chief Financial Officer | Mar 9, 2026 |
| Stephen F. Mahoney | President and CEO | Mar 9, 2026 |
| Jennifer Tousignant | Chief Legal Officer | Aug 20, 2026 |
| Radhika Tripuraneni | Chief Medical Officer | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignant | Sale | 10,000 | $24.50 |
| Aug 19, 2026 | Jennifer Tousignant | Sale | 4,212 | $24.50 |
| May 11, 2026 | Healthcare Fund Ii L.P. Fairmount | Buy | 1,176,470 | $17.00 |
| May 11, 2026 | Funds Management Llc Fairmount | Buy | 1,176,470 | $17.00 |
| May 11, 2026 | Healthcare Fund Ii Gp Llc Fairmount | Buy | 1,176,470 | $17.00 |
| Dec 31, 2025 | Jennifer Tousignant | Sale | 2,272 | $31.16 |
| Oct 23, 2025 | Healthcare Fund Ii Gp Llc Fairmount | Buy | 454,545 | $22.00 |
| Oct 23, 2025 | Healthcare Fund Ii L.P. Fairmount | Buy | 454,545 | $22.00 |
| Oct 23, 2025 | Funds Management Llc Fairmount | Buy | 454,545 | $22.00 |
VRDN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-342.60M | — | $-276.39M |
| Dec 31, 2024 | — | $-269.95M | — | $-232.32M |
| Dec 31, 2023 | — | $-237.73M | -5.31 | $-184.17M |
| Dec 31, 2022 | — | $-129.87M | -4.05 | $-93.84M |
| Dec 31, 2021 | — | $-79.41M | -6.66 | $-54.58M |
Latest balance sheet: total assets $1.10B, total liabilities $435.14M, cash $24.86M (as of Jun 30, 2026).
VRDN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $22.51 |
| May 5, 2026 | 8-K Item 2.02 (results) | $18.75 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $29.49 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $24.42 |
| Oct 21, 2025 | 8-K Item 2.02 (results) | $24.02 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $17.20 |
| May 6, 2025 | 8-K Item 2.02 (results) | $12.03 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $15.29 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $22.43 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on VRDN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.